KAEDI is a new drug research and development company in the clinical stage that uses leading synthetic biology technologies to develop novel cell therapy drugs for the clinically unmet needs of patients with solid tumors. Relying on its advanced synthetic biology technology platform- KD-SmCAR™, and the dual targeting CAR development platform-KD-ScCAR™. KAEDI has successfully developed a number of first-in-class cell therapy drug development pipelines for malignant solid tumors, including next-generation autologous and allogeneic CAR-T cell therapy pipelines. At present, KAEDI have been declared more than 30 CAR-related patents in CN and US, and 15 patents have been authorized, which is the leading level of CAR-T industry at home and abroad, among which the core pipeline KD-025 and KD-496 patents are the first authorized in China and US.
The pre-clinical research results of KD-025 CAR-T targeting NKG2DL for HCC and GBM have been successively published in the international authoritative Journal of tumor immunotherapy such as “Journal for ImmunoTherapy of Cancer” and “Cancer Immunology”. At the same time, the research results were presented at the American Oncology Clinical Annual Meeting ASCO. At present, KD-025 CAR-T IIT clinical trials are being carried out in well-known clinical centers in China, and many cases have been completed, with no obvious toxic and adverse reactions, and the product is safe and effective. The first domestic CAR-T (KD-025 cell injection) targeting NKG2DL for the treatment of solid tumors IND declaration was approved. At the same time, the world's first new double-targeted CAR-T (KD-496) cell injection entered IIT clinical trials.
In addition, KAEDI is promoting the next generation of allogeneic universal CAR-T/CAR-NK and other layouts, and is expected to build into a globally renowned enterprise for solid tumor cell therapy in the near future. The company has built a 3000 M2 GMP cell drug research and development and production center, and has completed nearly 100 million RMB of financing, and is currently in the process of B-round financing. At the same time, the company is promoting the construction of SynBio-DnCF™, a synthetic biology fully synthetic cell factory, which is expected to achieve new breakthroughs in the development of new fully synthetic cell or nucleic acid drugs in the near future.
The pre-clinical research results of KD-025 CAR-T targeting NKG2DL for HCC and GBM have been successively published in the international authoritative Journal of tumor immunotherapy such as “Journal for ImmunoTherapy of Cancer” and “Cancer Immunology”. At the same time, the research results were presented at the American Oncology Clinical Annual Meeting ASCO. At present, KD-025 CAR-T IIT clinical trials are being carried out in well-known clinical centers in China, and many cases have been completed, with no obvious toxic and adverse reactions, and the product is safe and effective. The first domestic CAR-T (KD-025 cell injection) targeting NKG2DL for the treatment of solid tumors IND declaration was approved. At the same time, the world's first new double-targeted CAR-T (KD-496) cell injection entered IIT clinical trials.
In addition, KAEDI is promoting the next generation of allogeneic universal CAR-T/CAR-NK and other layouts, and is expected to build into a globally renowned enterprise for solid tumor cell therapy in the near future. The company has built a 3000 M2 GMP cell drug research and development and production center, and has completed nearly 100 million RMB of financing, and is currently in the process of B-round financing. At the same time, the company is promoting the construction of SynBio-DnCF™, a synthetic biology fully synthetic cell factory, which is expected to achieve new breakthroughs in the development of new fully synthetic cell or nucleic acid drugs in the near future.